| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K |
| Revenues: |
| Two Customer | | | 52.3 | | | | | |
| Other Revenue | 0.0 | 0.1 | 0.1 | | | | | |
| Orthobiologics | 47.1 | 42.3 | 39.3 | | | | | |
| Other | 10.8 | 12.9 | | | | | | |
| Total revenues [+] | 58.0 | 55.3 | 53.3 | 64.7 | 72.2 | 82.6 | 90.0 | 59.3 |
| Products | | | | | | | 89.4 | 58.2 |
| Other | | | | | | | 0.6 | 1.2 |
| Other income | 0.0 | 0.1 | 0.1 | 0.2 | 0.4 | 0.1 | | |
| Revenue growth [+] | 4.9% | 3.6% | -17.5% | -10.4% | -12.6% | -8.2% | 51.7% | 68.0% |
| Other Revenue | -90.6% | -21.5% | | | | | | |
| Orthobiologics | 11.6% | 7.5% | | | | | | |
| Spinal Implant | -16.1% | -7.2% | | | | | | |
| Cost of goods sold | 25.8 | 22.8 | 18.9 | 22.2 | 28.7 | 32.5 | 27.7 | 20.3 |
| Gross profit | 32.1 | 32.5 | 34.4 | 42.5 | 43.5 | 50.1 | 62.3 | 39.1 |
| Gross margin | 55.4% | 58.8% | 64.5% | 65.7% | 60.2% | 60.6% | 69.2% | 65.9% |
| Selling, general and administrative [+] | 38.0 | 35.5 | 34.5 | 43.8 | 45.7 | 55.8 | 59.8 | 41.7 |
| Sales and marketing | 22.5 | 21.0 | 21.0 | 26.5 | 31.5 | 40.5 | 44.1 | 28.7 |
| General and administrative | 15.5 | 14.4 | 13.5 | 17.3 | 14.3 | 15.2 | 15.8 | 13.0 |
| Research and development | 0.9 | 0.9 | 0.7 | 0.9 | 1.7 | 2.4 | 3.4 | 2.5 |
| Other operating expenses | | | | | 1.6 | 2.2 | 1.0 | -1.8 |
| EBITDA [+] | -5.5 | -2.5 | 1.3 | 0.9 | -2.4 | -7.4 | 0.4 | -2.3 |
| EBITDA growth | 116.6% | -289.9% | 49.2% | -137.5% | -67.8% | -2031.1% | -116.7% | -48.0% |
| EBITDA margin | -9.4% | -4.6% | 2.5% | 1.4% | -3.3% | -8.9% | 0.4% | -3.9% |
| Depreciation | 1.2 | 1.3 | 2.0 | 3.0 | 3.2 | 3.8 | 2.8 | 1.5 |
| EBITA | -6.7 | -3.9 | -0.7 | -2.2 | -5.5 | -11.1 | -2.4 | -3.7 |
| EBITA margin | -11.5% | -7.0% | -1.2% | -3.3% | -7.7% | -13.5% | -2.6% | -6.3% |
| Amortization of intangibles | 0.1 | | 0.1 | 0.1 | 3.4 | 4.6 | 4.5 | 3.4 |
| EBIT [+] | -6.8 | -3.9 | -0.8 | -2.3 | -9.0 | -15.8 | -6.9 | -7.2 |
| EBIT growth | 75.3% | 413.2% | -66.7% | -74.9% | -43.2% | 129.9% | -4.4% | 34.1% |
| EBIT margin | -11.7% | -7.0% | -1.4% | -3.5% | -12.4% | -19.1% | -7.6% | -12.1% |
| Non-recurring items [+] | | | | | 51.1 | 22.1 | 0.7 | 4.9 |
| Asset impairment | | | | | 48.1 | 17.6 | | 0.2 |
| Interest expense, net [+] | 1.7 | 1.0 | 6.0 | 5.8 | 10.1 | 14.7 | 12.3 | 7.7 |
| Interest expense | 1.7 | 1.0 | 6.0 | 5.8 | 10.1 | 14.7 | 12.3 | 7.7 |
| Interest income | 0.0 | | | | | | | |
| Other income (expense), net [+] | | | | -0.1 | 0.1 | 0.1 | 0.4 | 0.1 |
| Gain (loss) on debt retirement | | | 15.1 | | | | | -2.3 |
| Gain (loss) on derivative instruments | | | | | 0.1 | 0.2 | 0.7 | 0.3 |
| Write-off of deferred debt issuance costs | | | 15.1 | | | | | -2.3 |
| Other | | | | -0.1 | 0.0 | -0.1 | -0.4 | 0.4 |
| Pre-tax income | -8.4 | -4.8 | -6.7 | -8.1 | -70.1 | -52.4 | -19.4 | -19.7 |
| Income taxes | 0.1 | 0.0 | 0.3 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 |
| Tax rate | | 0.0% | | | 0.0% | 0.0% | | 0.0% |
| Net income | -8.5 | -4.8 | -7.0 | -8.2 | -70.1 | -52.4 | -19.5 | -2.2 |
| Net margin | -14.6% | -8.8% | -13.2% | -12.7% | -97.1% | -63.4% | -21.7% | -3.7% |
| |
| Basic EPS [+] | ($0.09) | ($0.06) | ($0.25) | ($0.62) | ($5.97) | ($34.76) | ($18.46) | ($0.24) |
| Growth | 58.9% | -77.0% | -60.5% | -89.5% | -82.8% | 88.3% | 7588.1% | -86.4% |
| Diluted EPS [+] | ($0.09) | ($0.06) | ($0.25) | ($0.62) | ($5.97) | ($34.76) | ($18.46) | ($0.24) |
| Growth | 58.9% | -77.0% | -60.5% | -89.5% | -82.8% | 88.3% | 7588.1% | -86.4% |
| |
| Shares outstanding (basic) [+] | 94.1 | 85.5 | 28.5 | 13.2 | 11.7 | 1.5 | 1.1 | 9.1 |
| Growth | 10.1% | 199.8% | 116.5% | 12.1% | 678.7% | 42.8% | -88.3% | 52.1% |
| Shares outstanding (diluted) [+] | 94.1 | 85.5 | 28.5 | 13.2 | 11.7 | 1.5 | 1.1 | 9.1 |
| Growth | 10.1% | 199.8% | 116.5% | 12.1% | 678.7% | 42.8% | -88.3% | 52.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |